Nominations Now Open for 7th Annual Harrington Prize for Innovation in Medicine

National and international nominations are being sought for the 2020 Harrington Prize for Innovation in Medicine, which honors a physician-scientist who has moved science forward with achievements notable for innovation, creativity and the potential for clinical application.

The deadline for nominations is Aug. 27, 2019.

Nomination guidelines can be found at: HarringtonDiscovery.org/ThePrize.

The Harrington Prize, which carries a $20,000 honorarium, is a collaboration between The American Society for Clinical Investigation (ASCI), one of the nation’s oldest and most respected medical honor societies, and the Harrington Discovery Institute at University Hospitals in Cleveland, Ohio – part of The Harrington Project for Discovery & Development. The Harrington Discovery Institute is a nonprofit institute dedicated to supporting physician-scientists, and all scientists in areas of unmet therapeutic need, in their work to transform discoveries into medicines for the benefit of society.

Both organizations recognize the challenges associated with turning discoveries into medicines, and they are eager to highlight those who have navigated the path successfully or whose work has led to novel treatments.

A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board will review the nominations and select the awardee. In addition to the honorarium, the 2020 recipient will deliver the Harrington Prize Lecture at the 2020 Joint Meeting of the Association of American Physicians (AAP), the ASCI, and the American Physician Scientists Association (APSA) April 3-5, 2020; will lecture at the 2020 Harrington Discovery Institute Symposium May 20-21, 2020; and will publish a personal essay in the Journal of Clinical Investigation.

Previous award winners are Carl H. June, MD (2019); Helen H. Hobbs, MD (2018); Daniel J. Drucker, MD, Joel F. Habener, MD, and Jens J. Holst, MD, DMSc (2017 co-recipients); Jeffrey M. Friedman, MD, PhD (2016); Douglas R. Lowy, MD (2015); and Harry C. Dietz, MD (2014).

For questions or more information about the nomination requirements, visit HarringtonDiscovery.org/ThePrize or contact Bronwyn Monroe, Harrington Discovery Institute Program Director, at Bronwyn.Monroe@HarringtonDiscovery.org


The American Society for Clinical Investigation
Founded in 1908, the American Society for Clinical Investigation is one of the oldest and most esteemed nonprofit honor societies of physician-scientists. Membership is by election only, and only researchers who are 50 years of age or younger are eligible for nomination to the Society. Therefore, membership in the ASCI is a recognition of a researcher’s significant contributions, at a relatively young age, to the understanding of human disease. The Society counts among its ranks more than 3,000 members, many of whom are leaders in academic medicine and industry. Many members have been recognized by election to the U.S. National Academy of Sciences and the U.S. National Academy of Medicine. The ASCI is also proud to have among its membership winners of the Nobel Prize and the Lasker Award. The ASCI convenes an annual meeting with the Association of American Physicians, and the Society self-publishes the prestigious Journal of Clinical Investigation (founded 1924), and JCI Insight (founded 2016).

Harrington Discovery Institute
The Harrington Discovery Institute at University Hospitals in Cleveland, OH—part of The Harrington Project for Discovery & Development—aims to advance medicine and society by enabling our nation’s most inventive scientists to turn their discoveries into medicines that improve human health. The institute was created in 2012 with a $50 million founding gift from the Harrington family and instantiates the commitment they share with University Hospitals to a Vision for a ‘Better World.’

The Harrington Project for Discovery & Development
The Harrington Project for Discovery & Development (The Harrington Project), founded in February 2012 by the Harrington Family and University Hospitals of Cleveland, is a $300 million national initiative built to bridge the translational ‘valley of death.’ It includes the Harrington Discovery Institute and BioMotiv, a for-profit, mission-aligned drug development company that accelerates early discovery into pharma pipelines.

For more information about The Harrington Project and the Harrington Discovery Institute, visit: HarringtonDiscovery.org.